Serrapeptase is a serine protease enzyme produced by the enterobacterium Serratia marcescens, first isolated from silkworm intestines where it dissolves the silkworm's cocoon. It is not found in food but is manufactured through microbial fermentation and formulated as an enteric-coated supplement to survive stomach acid. It has been used clinically in Japan and parts of Europe for decades as an anti-inflammatory and mucolytic agent, though regulatory approval status varies significantly by country.

Serrapeptase works primarily by hydrolyzing bradykinin, fibrin, and other inflammatory peptides at sites of tissue damage, which reduces localized swelling and pain signaling. It also degrades viscous mucoproteins in mucus secretions, making them thinner and easier to clear from respiratory passages. Some research suggests it may inhibit biofilm formation and enhance antibiotic penetration into infected tissue, though this evidence is largely from in vitro and animal models.

Serrapeptase must be taken as an enteric-coated or delayed-release formulation to ensure intestinal absorption intact. Standard commercial forms include enteric-coated tablets and capsules ranging from 10 mg (approximately 20,000 SU) to 60 mg (approximately 120,000 SU). Powder or non-coated formulations are unlikely to deliver active enzyme systemically.

• Post-surgical and post-traumatic swelling
• Sinusitis and chronic rhinosinusitis
• Musculoskeletal pain and inflammation
• Carpal tunnel syndrome
• Breast engorgement and fibrocystic breast conditions

• Delayed wound healing complications (by reducing fibrin accumulation at surgical sites, supported by post-surgical trial data)
• Mucus impaction and sinopulmonary obstruction in chronic rhinosinusitis (supported by mucolytic clinical trials)

Serrapeptase is a microbially-derived enzyme supplement with no direct food source — dietary proteins do not supply this specific protease. However, a diet rich in other proteolytic-enzyme-containing foods supports a broadly similar anti-inflammatory and digestive pathway: fresh pineapple (bromelain), raw papaya (papain), fresh ginger (zingibain), kefir and fermented dairy (microbial proteases), and fermented soy products such as natto (nattokinase) are all natural sources of proteolytic enzymes with overlapping anti-inflammatory and fibrinolytic mechanisms. Minimizing ultra-processed foods and refined sugars supports a lower systemic inflammatory baseline, complementing serrapeptase therapy. Foods rich in zinc (pumpkin seeds, legumes, shellfish) support endogenous protease activity, which aligns with serrapeptase's zinc-dependent mechanism.

• Nausea and mild GI upset (most common, particularly with non-enteric-coated preparations)
• Skin rash or urticaria (hypersensitivity reactions)
• Muscle aches and joint pain (reported in some users at higher doses)
• Appetite disturbance
• Rare: pneumonitis or pulmonary eosinophilia (case reports, primarily from Japan)
• Rare: blood-tinged sputum (due to mucolytic activity in respiratory secretions)

• Recommended daily: 10 mg to 60 mg (approximately 20,000–120,000 SU) per day in divided doses; most clinical trials used 10–30 mg/day (20,000–60,000 SU/day) for anti-inflammatory indications. Higher doses (60,000–120,000 SU/day) are used for mucolytic purposes in some protocols.
• Best time of day: Between meals — typically 30–60 minutes before meals or at least 2 hours after eating to ensure enzymatic activity is not consumed by food digestion.
• With or without food: Must be taken away from food. Enteric-coated tablets/capsules should be swallowed whole and not crushed or chewed.
• Time to effect: Swelling and pain relief: 3–10 days; mucolytic benefit: 1–4 weeks; some studies report benefits beginning within 3 days of initiation.
• How long to take it: Clinical trials typically ran 1–4 weeks for acute indications. For chronic conditions, use beyond 4 weeks should be supervised by a healthcare provider. No standard cycling protocol is established; periodic reassessment every 4 weeks is advisable.